GlassScriptPhysician profile
Dariush Shahsavari
NPI 1932549433
$1,820.22
in general payments reported to CMS, 2019-2025
13 companies · $18.17 in 2025
The $18.17 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $292 · 2023: $1,328 · 2024: $182 · 2025: $18.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776 · Travel and Lodging: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.78 |
| Travel and Lodging | $752.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $652.29 | 2023 | Fusion |
| Cook Medical LLC | $232.47 | 2023-2025 | Fusion, Zenith Spiral-Z |
| Abbvie INC. | $149.36 | 2023 | Rinvoq, Skyrizi |
| Boston Scientific Corporation | $133.93 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.25 | 2023-2024 | Xifaxan |
| Steris Corporation | $101.16 | 2022 | |
| Laborie Medical Technologies Corp. | $97.43 | 2022 | |
| Qol Medical, LLC | $96.56 | 2024 | Sucraid |
| Gi Supply, INC. | $93.44 | 2022 | |
| Intercept Pharmaceuticals, INC. | $64.26 | 2023 | Ocaliva |
| Lilly USA, LLC | $31.14 | 2024 | Omvoh |
| Genzyme Corporation | $18.19 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.74 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dariush Shahsavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.